Evoke Pharma (NASDAQ:EVOK) (NASDAQ: EVOK) is a specialty biopharmaceutical company focused on the development and commercialization of treatments for gastrointestinal motility disorders. Headquartered in San Diego, California, the company concentrates its efforts on novel formulations designed to address significant unmet needs in patients suffering from delayed gastric emptying and related symptoms. Through targeted research and development, Evoke Pharma aims to bring innovative therapies to market that enhance clinical efficacy and patient quality of life.
The company’s lead product, GIMOTI® (metoclopramide) nasal spray, is approved in the United States for the acute and recurrent treatment of symptoms in adults with diabetic and idiopathic gastroparesis. GIMOTI’s unique nasal formulation allows for rapid absorption, offering an alternative to existing oral therapies that are often limited by gastrointestinal transit issues. Beyond GIMOTI, Evoke Pharma continues to explore additional proprietary formulations and delivery mechanisms to expand its pipeline and address broader gastrointestinal indications.
Founded in 2004, Evoke Pharma has evolved from early-stage research into a commercially oriented enterprise. The company completed a public listing on the NASDAQ in 2013, providing the capital necessary to advance clinical programs and scale manufacturing capabilities. Over the years, Evoke Pharma has entered strategic collaborations and licensing discussions to support international commercialization, particularly targeting markets in Europe and Asia where gastroparesis prevalence continues to rise.
Leadership at Evoke Pharma is led by President and Chief Executive Officer Peter W. Greenleaf, who brings more than two decades of pharmaceutical industry experience, including roles in commercial operations and corporate development. Supported by a seasoned management team and board of directors with deep expertise in drug development, regulatory affairs and market access, the company is well positioned to execute its mission of delivering differentiated gastrointestinal therapies to patients worldwide.
